U.S. Stem Cell, Inc.
U.S. Stem Cell, Inc. (USRM) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
usrm · pe ratio · data through Jun 9, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMInsufficient PE history data (fewer than 3 valid fiscal years).
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
U.S. Stem Cell, Inc.You USRM | $0M | N/A | — | — |
 AVAX Technologies, Inc. AVXT | $0M | N/A | — | -$0.05 |
 Braxia Scientific Corp. BRAXF | $0M | N/A | — | -$0.06 |
 Baseline Productions, Inc. BSSP | $0M | N/A | — | -$0.01 |
 DNAPrint Genomics, Inc. DNAG | $0M | N/A | — | -$0.03 |
 Interpharm Holdings, Inc. IPAH | $0M | N/A | — | -$0.22 |
 LadRx Corporation LADX | $0M | N/A | — | -$3210.89 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for U.S. Stem Cell, Inc. (USRM) measures how much investors pay for each dollar of the company's trailing earnings. USRM's current PE ratio of N/A is calculated by dividing its stock price of $0.00 by its TTM earnings per share of —.
Frequently asked questions
USRM pe ratio · 6 questionsUSRM's current PE ratio is N/A as of 2026-06-09, based on a stock price of $0.00 and TTM EPS of —. Data sourced from Financial Modeling Prep via USRM's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · U.S. Stem Cell, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09